Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 8/20 | 0.43 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | CA12 | O43570 | 7/20 | 0.43 |
| ▸ | CA9 | Q16790 | 7/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654204 | 1.00 | MEN1 (0.57) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL2917277 | 0.89 | MEN1 (0.68) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL29154833 | 0.88 | MEN1 (0.61) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL30163663 | 0.88 | MEN1 (0.61) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL21985071 | 0.88 | MEN1 (0.61) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL5019056 | 0.87 | MEN1 (0.59) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL29832942 | 0.86 | TDP1 (0.63) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL4383623 | 0.86 | TDP1 (0.63) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL397759 | 0.85 | MEN1 (0.61) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL5761580 | 0.83 | MEN1 (0.59) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223306-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIOVENTURES, INC., | 2025-07-10 | — | — | US | disclosed |
| CN-119522215-A | TEAD inhibitors and methods of use | 思博睿生物探索公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4496789-A1 | TEAD INHIBITORS AND METHODS OF USE | Sporos Biodiscovery, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2023183437-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIODISCOVERY, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-3898629-B1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| CN-108137545-A | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | 美国安进公司 | 2018-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | MEN1 856/4885GAA 1186/4885KMT2A 3310/4885 |
| US-20250223306-A1 | TEAD INHIBITORS AND METHODS OF USE | TEAD1, TEAD2, TEAD3 | MEN1 4168/4885GAA 1609/4885KMT2A 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.